Trial Profile

A Phase 1 study of ONO-4538 in combination with chemotherapy in patients with stage IIIB/IV or recurrent NSCLC

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Paclitaxel; Pemetrexed
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Ono Pharmaceutical

Most Recent Events

01 Jun 2020 Results published in the Cancer Science
12 Feb 2018 Planned End Date changed from 1 Mar 2017 to 1 Mar 2020.
18 Oct 2017 Results (n=24) assessing long term follow up of tolerability, safety and pharmacokinetics presented at the 18th World Conference on Lung Cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com